Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/009770METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY
WO 02.02.2023
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/038749 Applicant TEVOGEN BIO, INC. Inventor SAADI, Ryan
Disclosed herein are methods of preparing peptide specific cytotoxic T cells (CTLs) against an emerged strain of a virus. The methods include providing an initial peptide composition specific to a prior strain of a virus, against which prior CTLs were sensitized, wherein the prior CTLs have reduced efficacy against an emerged strain of a virus relative to their efficacy against the prior strain of the virus; identifying an immunodominant peptide against a prior strain of a virus in an initial peptide composition; reducing the proportion of an immunodominant peptide in an initial peptide composition to yield an immunodominant-peptide- diluted peptide composition; and sensitizing mononuclear cells with an immunodominant- peptide-diluted peptide composition, thereby producing expansion of the peptide specific CTLs against an emerged strain of a virus. The virus can be SARS-COV2 (COVID-19) and the emerged strain can be Delta or Omicron BA.2.75.
2.WO/2023/007409EAST COAST FEVER ANTIGENIC CONSTRUCTS
WO 02.02.2023
Int.Class A61K 39/018
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
002Protozoa antigens
015Hemosporidia antigens, e.g. Plasmodium antigens
018Babesia antigens, e.g. Theileria antigens
Appl.No PCT/IB2022/056970 Applicant UNIVERSITY OF CAPE TOWN Inventor WILLIAMSON, Anna-Lise
This invention relates to a chimaeric BLV-Gag VLP which contains T. parva p67 and/or gp34 antigens on its surface, the invention also relates to vectors comprising nucleic acids encoding the BLV-Gag proteins; and T. parva p67 and/or T. parva gp34 proteins. The invention specifically relates to the chimaeric BLV-Gag VLPs described herein, methods of producing the chimaeric BLV-Gag VLPs and pharmaceutical compositions either comprising the chimaeric BLV-Gag VLPs and/or vectors comprising the nucleic acids encoding the recombinant proteins which make up the chimaeric BLV-Gag VLPs. More specifically, the invention relates to a lumpy skin disease virus vaccine encoding the chimaeric BLV-Gag VLPs of the invention.
3.WO/2023/005805GENERAL AFFINITY EPITOPE POLYPEPTIDE FOR HUMAN RHINOVIRUS, AND ANTIBODY AND USES THEREOF
WO 02.02.2023
Int.Class C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
Appl.No PCT/CN2022/107144 Applicant BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Inventor CHENG, Tong
The present invention belongs to the field of immunobiology, and relates to an epitope polypeptide, such as a general affinity epitope polypeptide for human rhinovirus, and the use thereof. The present invention further relates to an antibody capable of binding to the epitope polypeptide and the use thereof. The present invention further relates to the use of the affinity epitope polypeptide or the antibody in the preparation of drugs or in methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus. The affinity epitope polypeptide and the antibody can be used in drugs or methods for treating and/or preventing and/or diagnosing human rhinovirus and/or identifying a titer of human rhinovirus and/or identifying a titer of a neutralizing antibody of human rhinovirus.
4.WO/2023/008881EXPRESSION SYSTEM, AND NUCLEIC ACID-BASED PHARMACEUTICAL COMPOSITION COMPRISING SAME
WO 02.02.2023
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Appl.No PCT/KR2022/010978 Applicant SML BIOPHARM CO., LTD. Inventor NAM, Jae Hwan
Disclosed is a nucleic acid molecule comprising: a translational regulatory element having a translation initiation activity; and a coding region, which is operably linked to the translational regulatory element and consists of a nucleotide encoding an immunogen of an influenza virus or a severe fever with thrombocytopenia syndrome virus (SFTSV), or a fragment thereof. The nucleic acid molecule or an expression system in which the nucleic acid molecule is inserted can be used in a pharmaceutical composition for treating or preventing influenza or SFTS, for example, that of an mRNA vaccine or a gene therapy platform.
5.WO/2023/006062NUCLEIC ACID VACCINES FOR MUTANT CORONAVIRUS
WO 02.02.2023
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2022/108920 Applicant SUZHOU ABOGEN BIOSCIENCES CO., LTD. Inventor YING, Bo
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
6.WO/2023/009977METHODS AND COMPOSITIONS FOR NOROVIRUS CHIMERIC THERAPEUTICS
WO 02.02.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/US2022/074103 Applicant THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor BARIC, Ralph, Steven
The present invention is directed to methods and compositions for GII.3/GII.4 chimeric norovirus capsid proteins comprising one or more amino acid substitutions. Additionally provided are synthetic backbone molecules, norovirus P particles, synthetic nanoparticles, scaffold immunogens, nucleic acids, mimitopes, polypeptides, virus replicon particles (VRPs), virus like particles (VLPs), vectors, cells, and compositions comprising the same.
7.WO/2023/009264COMPOSITIONS FOR OPTIMIZED INFLUENZA PEPTIDE VACCINES
WO 02.02.2023
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/US2022/035317 Applicant THINK THERAPEUTICS, INC. Inventor GIFFORD, David
Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 49. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 81 to 143. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137515 to 137675. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137682 to 137830.
8.WO/2023/009984COVID-19 IMMUNE RESPONSE ASSAY METHOD
WO 02.02.2023
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/US2022/074112 Applicant ORASURE TECHNOLOGIES, INC. Inventor YOUNG, Janean A.
Disclosed herein are assay methods and kits for for assessing the strength of the immune response to SARS-CoV-2 virus in a subject by allowing for rapid and efficient detection of neutralizing antibodies (NAbs) from serum of vaccinated and non-vaccinated subjects. The assay method can be conducted in a biosafety level 2 setting, and uses highly-purified, monomeric SARS-Cov-2-Spikel which leads to improved sensitivity and specificity over current state of the art assays.
9.20230031629ANTIGEN LOADING
US 02.02.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17782263 Applicant DendroCyte BioTech Pty Ltd. Inventor Georgina Jane CLARK

The disclosure relates to a method of antigen loading an antigen presenting cell or precursor thereof with a target antigen for presentation of the target antigen to a T cell, comprising contacting the antigen presenting cell or precursor thereof with a CD300f binding protein in the presence of the target antigen The disclosure also relates to compositions for antigen loading antigen presenting cells or precursors thereof, to immunoconjugates for antigen loading antigen presenting cells or precursors thereof, and use of antigen-loaded antigen presenting cells and immunoconjugates for promoting or increasing a T cell response to a target antigen in a subject.

10.WO/2023/010015COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HEPATITIS B AND D
WO 02.02.2023
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/074160 Applicant SVENSKA VACCINFABRIKEN PRODUKTION AB Inventor SÄLLBERG, Matti
Disclosed herein are immunogenic compositions or product combinations of engineered hepatitis B and hepatitis D nucleic acids, genes, peptides, or proteins that can be used to elicit an immune response against a hepatitis B and/or hepatitis D infection. Also disclosed are methods of using the immunogenic compositions or product combinations in subjects to generate immune responses against HBV and/or HDV by administering the compositions or combinations, for example, with a nucleic acid prime and polypeptide boost approach.